



22nd November 2016

BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	18956.69	+0.47%	+8.79%
S&P 500	2198.18	+0.75%	+7.55%
Nasdaq	5368.86	+0.89%	+7.22%
Nikkei	18162.94	+0.31%	-4.87%
Stoxx 600	340.235	+0.25%	-6.99%
CAC 40	4529.58	+0.56%	-2.32%
Oil /Gold			
Crude WTI	45.69	0.00	+22.82%
Gold (once)	1213.97	+0.53%	+14.27%
Currencies/Rates			
EUR/USD	1.06225	+0.45%	-2.21%
EUR/CHF	1.07195	+0.22%	-1.42%
German 10 years	0.2	-1.41%	-68.50%
French 10 years	0.741	-1.32%	-24.44%

Economic releases :

Date	
22nd-Nov	10h30 GB Public finances NCR Oct. 12h00 GB - CBI Industrials trends survey 16h00 US - Existing home sales 16h00 US - Richmond Fed Manuf. Index

Upcoming BG events :

Date	
24th-Nov	CAP GEMINI (BG Lunch with IR)
24th-Nov	IMERYIS (BG London roadshow with IR)
24th-Nov	IMERYIS (BG London roadshow with IR)
28th-Nov/ 29th-Nov	2nd Paris Consumer Conference
30th-Nov	VALEO (BG Lunch with IR)
5th-Dec	Reverse roadshow in Paris / Construction

Recent reports :

Date	
21st-Nov	Innate - Still time to jump on the bandwagon
21st-Nov	Car Parts -What if market went too far down on auto suppliers?
18th-Nov	FOCUS FRESENIUS Steady as she goes
18th-Nov	FOCUS ACTELION Several upsides to play in an exciting 2017 year
16th-Nov	VEOLIA ENVIRONNEMENT EBITDA growth remains the key driver
9th-Nov	VOLTALIA Starting to play with the big boys

List of our Reco & Fair Value : Please click here to download



GENMAB

BUY, Fair Value DKK1900 vs. DKK1650 (+53%)

And it did it again... Dara approved well before planned calendar! New FV of DKK1,900

And it did it again! Daratumumab has obtained its US label expansion (well before planned calendar) for 1/ patients with myeloma who received at least one prior line of therapy, and 2/ as part of a combination regimen with either CELG's Revlimid or JNJ's Velcade. And as some sales under this new label are likely to happen anytime soon, GEN now expects a USD65m milestone payment (hence the upward revision to its financial guidance). Our FV is raised from DKK1,650 to DKK1,900, as we notably retain both a higher PoS and a lower WACC for "dara" as a 2nd line option in MM.

ZEALAND

BUY, Fair Value DKK223 vs. DKK172 (+91%)

The approval of Soliqua in the US opens a new phase for Zealand

Yesterday the FDA approved both Sanofi's Soliqua and Novo's Xultophy for patients with type II diabetes uncontrolled with either a basal insulin or a GLP1 analogue. Soliqua has been approved with a unique strength and a unique pen which includes 100 units/mL and 33 mcg/mL of glargine and lixi respectively and can deliver 15-60 units of glargine and up to 20 mcg of lixi once-daily. Sanofi plans to launch Soliqua in the US in January 2017 whereas Novo expects to launch Xultophy in H1 2017. The approval triggers a payment of USD25m from Sanofi to Zealand that will reduce the size of the bond.

In brief...

ASTRAZENECA, FDA lifts partial hold on H&N trials with durvalumab

COMPASS GROUP, First take FY results: slightly lower expectation after challenging Q4. Outlook positive even if H1 will remain tough.

ESSILOR, FY 2016 outlook revised down again due to the US market

NOVO NORDISK, Xultophy approved in the US

SANOFI, Sanofi can try to defend its Diabetes franchise with Soliqua

FOCUS Orpea More than ever a BUY (Fair Value EUR86 BUY)

For a while, despite strong results, the stock has been under pressure and is suffering in particular from the potential impact of an interest rate upturn following the US presidential election on asset valuations and/or debt. In our view, this is an irrational overreaction. Therefore, with top-line growth of at least 10% (o/w 5% organic) with margin improvements, we are confirming our recently upgraded FV

Healthcare

Genmab

Price DKK1,245

And it did it again... Dara approved well before planned calendar! New FV of DKK1,900

Fair Value DKK1900 vs. DKK1650 (+53%)

BUY

Bloomberg	GEN DC
Reuters	GEN.CO
12-month High / Low (DKK)	1,266 / 638.0
Market Cap (DKKm)	75,136
Ev (BG Estimates) (DKKm)	71,397
Avg. 6m daily volume (000)	372.4
3y EPS CAGR	54.0%

And it did it again! Daratumumab has obtained its US label expansion (well before planned calendar) for 1/ patients with myeloma who received at least one prior line of therapy, and 2/ as part of a combination regimen with either CELG's Revlimid or JNJ's Velcade. And as some sales under this new label are likely to happen anytime soon, GEN now expects a USD65m milestone payment (hence the upward revision to its financial guidance). Our FV is raised from DKK1,650 to DKK1,900, as we notably retain both a higher PoS and a lower WACC for "dara" as a 2nd line option in MM.

	1 M	3 M	6 M	31/12/15
Absolute perf.	9.7%	12.3%	10.2%	35.7%
Healthcare	-3.5%	-6.8%	-4.7%	-13.9%
DJ Stoxx 600	-1.2%	0.0%	0.7%	-7.0%

ANALYSIS

- **FDA approval c.1 month after the granting of a priority review.** In the end, "dara" has obtained its US label expansion for 1/ patients with myeloma who received at least one prior therapy, and 2/ as part of a combination regimen with either lenalidomide/dexamethasone or bortezomib/dexamethasone. And cherry on the cake, the approval was given well before planned calendar (as the PDUFA date was previously set for 17th February 2017).
- **Financial targets further revised up.** As some sales under this new label are likely to happen anytime soon, GEN now expects a USD65m milestone payment this year. But as this event was obviously not anticipated, guidance has been updated to include it (see table below – and note that the cash position is left unchanged as the payment should be received shortly after year-end).
- **We have lifted our 2016 sales estimates slightly.** Note that the company is also sticking to its target of DKK400-450m of royalties from Janssen associated with the commercialisation of "dara" (implying WW sales of USD500-550m), which could prove to be conservative given 1/ the depth of the 2L myeloma market; 2/ the added therapeutic benefit that dara could bring, whether in terms of safety or efficacy; and 3/ the already very positive feedback from physicians (and we believe the follow-up data to be presented at the upcoming ASH will further sustain this momentum). For our part, we have moved up our 2016 sales estimates for the compound by +USD20m to USD570m, and it goes without saying that we have also made a few changes to our 2017 figures (but nothing very significant).

YEnd Dec. (DKKm)	2015	2016e	2017e	2018e
Sales	1,133	1,715	2,204	3,497
% change		51.3%	28.5%	58.7%
EBITDA	554	878	1,247	2,445
EBIT	730.4	878.4	1,247	2,445
% change		20.3%	42.0%	96.0%
Net income	587.3	883.4	1,131	2,214
% change		50.4%	28.1%	95.7%

	2015	2016e	2017e	2018e
Operating margin	64.5	51.2	56.6	69.9
Net margin	67.4	51.5	51.3	63.3
ROE	21.9	22.5	20.6	28.7
ROCE	-15,400	458.1	293.6	386.9
Gearing	-100.2	-95.1	-93.0	-92.6

(DKK)	2015	2016e	2017e	2018e
EPS	9.71	14.32	18.12	35.45
% change	-	47.4%	26.5%	95.7%
P/E	NS	86.9x	68.7x	35.1x
FCF yield (%)	NM	NM	NM	NM
Dividends (DKK)	0.00	0.00	0.00	0.00
Div yield (%)	NM	NM	NM	NM
EV/Sales	63.2x	41.6x	31.8x	19.4x
EV/EBITDA	129.3x	81.3x	56.1x	27.8x
EV/EBIT	98.1x	81.3x	56.1x	27.8x

Fig. 1: GEN – BG estimates vs updated financial guidance

	BG	New guidance	Former guidance
GEN Revenues (DKKm)	1,715	1,650-1,700	1,200-1,250
"Dara" royalties (DKKm)	466	400-450	400-450
Operating expenses (DKKm)	836	800-850	800-850
Operating income (DKKm)	878	825-8753	375-425
Cash position at year end (DKKm)	3,739	3,650-3,750	3,650-3,750

Source : Company Data; Bryan Garnier & Co. ests.

VALUATION

- **We have raised our FV from DKK1,650 to DKK1,900** to take account of both 1/ a higher probability of success (100% vs 80% previously), and a slightly lower WACC (8.0% vs 9.0% - as commercial risks are carried by GEN's partner, i.e. JNJ) for "dara" as a second-line option for myeloma. We also stick to our Buy recommendation, especially since we continue to see pretty dense newsflow in the coming weeks/months.

NEXT CATALYSTS

- **5th December:** R&D Day/ASH update.
- **H1 2017:** Phase IIb results for daratumumab in NHL (monotherapy) + Phase III as a 1L option in myeloma (in combination with melaphalan, bortezomib and dexamethasone).

[Click here to download](#)



Analyst :
 Mickael Chane Du
 33(0) 1 70 36 57 45
 mchanedu@bryangarnier.com

Sector Team :
 Eric Le Berrigaud
 Marion Levi
 Hugo Solvet

Healthcare

Zealand

Price DKK117.00

The approval of Soliqua in the US opens a new phase for Zealand

Fair Value DKK223 vs. DKK172 (+91%)

BUY

Bloomberg	ZEAL DC
Reuters	22Z.F
12-month High / Low (DKK)	155.0 / 87.0
Market Cap (DKK)	3,050
Ev (BG Estimates) (DKK)	2,862
Avg. 6m daily volume (000)	123.6
3y EPS CAGR	

Yesterday the FDA approved both Sanofi's Soliqua and Novo's Xultophy for patients with type II diabetes uncontrolled with either a basal insulin or a GLP1 analogue. Soliqua has been approved with a unique strength and a unique pen which includes 100 units/mL and 33 mcg/mL of glargine and lixi respectively and can deliver 15-60 units of glargine and up to 20 mcg of lixi once-daily. Sanofi plans to launch Soliqua in the US in January 2017 whereas Novo expects to launch Xultophy in H1 2017. The approval triggers a payment of USD25m from Sanofi to Zealand that will reduce the size of the bond.

	1 M	3 M	6 M	31/12/15
Absolute perf.	17.0%	-3.7%	5.4%	-22.8%
Healthcare	-3.5%	-6.8%	-4.7%	-13.9%
DJ Stoxx 600	-1.2%	0.0%	0.7%	-7.0%

ANALYSIS

Soliqua has been approved by the FDA in a unique pen device containing 100 units/mL of glargine and 33 mcg/mL of lixisenatide.

YEnd Dec. (DKKm)	2015	2016e	2017e	2018e
Sales	165.4	255.9	320.4	510.4
% change		54.7%	25.2%	59.3%
EBITDA	-75.3	6.4	22.2	168
EBIT	-81.3	0.4	16.2	161.3
% change		NS		
Net income	-114.0	-83.9	-42.8	12.0
% change		26.4%	49.0%	NS

Of course, not everything is fixed with the approval of the drug and the period of negotiations with payers about the right level of discount and rebate to offer to gain access to the reimbursement list in the US is no just beginning. With the simultaneous approval of Novo's Xultophy, it is fair to assume that Sanofi and Novo-Nordisk will together discuss with payers at the same time. And we know that the equation is markedly different for the two players. On one hand, Novo-Nordisk has a strong GLP1 franchise in place that is estimated to generate higher margins than insulins and that Novo has to protect, if only because semaglutide will come next. With a list price of USD16-18 per day in the US for Victoza alone and a list price of USD10-12 for Tresiba, it is difficult to imagine a price for Xultophy that is below USD20 per day. On the other hand, Sanofi has of course a strong Lantus franchise but it is no longer a growth driver since prices have started going down whereas first biosimilar (Lilly's Basaglar) is expected mid-December. Lantus is about USD10 per day but discount rate is probably close to 30%. So a price for Soliqua between USD12 and Victoza's USD16-18 would be beneficial for the mix product and margins at Sanofi while offering an attractive proposition to payers. Because Sanofi is under pressure to save as much as possible from its diabetes franchise and because Xultophy is a better product, price is key to the success of Soliqua in our view. And the objective is to take market share as quickly as possible. It is estimated that about 1 million of basal insulin takers (mainly Lantus ones) are not controlled and candidates for a fixed-dose combination. Using a net daily price of USD12, this would create a market of at least USD4bn.

	2015	2016e	2017e	2018e
Operating margin	NM	NM	NM	NM
Net margin	NM	NM	NM	NM
ROE	NM	NM	NM	NM
ROCE	NM	NM	NM	NM
Gearing	-50.4	-80.5	-59.1	-44.2

VALUATION

With the final approval now, we move our PoS from 90% to 100% (considering also the positive opinion received from the CHMP). To sit on the safe side, we have however decided to fine-tune our estimates for Lyxumia and Soliqua to factor in the tough market conditions for drugs addressing chronic diseases in general and diabetes in particular. We have lowered Soliqua's peak sales to USD1.8bn (vs USD2bn) and have included a softer ramp-up.

(DKK)	2015	2016e	2017e	2018e
EPS	-4.82	-0.82	-0.22	5.13
% change	-	83.0%	73.4%	NS
P/E	NS	NS	NS	22.8x
FCF yield (%)	NM	NM	NM	NM
Dividends (DKK)	0.00	0.00	0.00	0.00
Div yield (%)	NM	NM	NM	NM
EV/Sales	17.7x	11.2x	9.1x	5.6x
EV/EBITDA	NS	449.9x	131.1x	17.0x
EV/EBIT	NS	7942.7x	179.8x	17.7x

However, our major influential decision has been to align the WACC used to discount mainstream cash-flows from lixisenatide-derived products at Sanofi with that used to discount royalties (low double-digit) paid by Sanofi to Zealand, which not only makes sense but now that the drug is approved cannot be done in a different way as we are talking about a single and unique product. NPV of Soliqua with 100% PoS would therefore move up from DKK99 (with WACC of 15.6%) to DKK152 (with WACC of 6.88% i.e. Sanofi's WACC).

All included [PS: -DKK21 – PoS: +DKK10 – WACC: +DKK62], our new FV is DKK223. We reaffirm a strong BUY on Zealand that can now safely think about how to best manage its proprietary pipeline and create value with no need to make overly difficult arbitrages.

NEXT CATALYSTS

Today 4pm: Conference Call on the US approval of Soliqua
 January 2017: EMA decision and US launch of Soliqua

[Click here to download](#)



Analyst :
 Eric Le Berrigaud
 33(0) 1 56 68 75 33
 eleberrigaud@bryangarnier.com

Sector Team :
 Mickael Chane Du
 Marion Levi
 Hugo Solvet

Healthcare

AstraZeneca

Price 4,326p

FDA lifts partial hold on H&N trials with durvalumab

Fair Value 5100p (+18%)

BUY

Bloomberg	AZN LN
Reuters	AZN.L
12-month High / Low (p)	5,220 / 3,774
Market Cap (GBPm)	54,719
Avg. 6m daily volume (000)	2 843

	1 M	3 M	6 M	31/12/15
Absolute perf.	-12.7%	-14.5%	11.1%	-6.3%
Healthcare	-3.5%	-6.8%	-4.7%	-13.9%
DJ Stoxx 600	-1.2%	0.0%	0.7%	-7.0%

	2015	2016e	2017e	2018e
P/E	12.7x	12.8x	16.3x	16.4x
Div yield (%)	5.2%	5.2%	5.2%	5.2%

ANALYSIS

- AstraZeneca has announced today that the FDA has lifted the partial clinical hold put on patient recruitment in head and neck squamous cell carcinoma (H&N) trials involving durvalumab in monotherapy or in combination with tremelimumab. Late last month, EAGLE and KESTREL phase III trials saw patient recruitment suspended after the report by AstraZeneca to the FDA of a higher-than-expected incidence of bleeding events. Although patients with H&N cancer are more likely to have bleeds, this may have been drug-related, hence the decision to stop including new patients.
- After careful consideration, the agency has lifted the partial clinical hold, suggesting that no correlation between extra bleedings and the drug can be established. As a consequence, AstraZeneca mentioned that it has already re-opened KESTREL to recruitment whereas EAGLE will soon be re-opened too.
- This is good news for AstraZeneca's PD-L1 franchise because head & neck was the second most important indication for durvalumab-based treatments after lung cancer and a setback would have caused a meaningful sales cut (probably by about one-fifth).

VALUATION

- Considering the weight of oncology in AstraZeneca's future sales, as well as its influence on the profit margin and profit growth, everything has to work well to support an investment case that is heavily dependent on the pipeline.

NEXT CATALYSTS

- 2nd February 2017: Full-year 2016 results

[Click here to download](#)

Eric Le Berrigaud, eleberrigaud@bryangarnier.com

Business Services

Compass Group

Price 1,381p

First take FY results: slightly lower expectation after challenging Q4. Outlook positive even if H1 will remain tough.

Fair Value 1450p (+5%)

NEUTRAL

Bloomberg	CPG LN
Reuters	CPG.L
12-month High / Low (p)	1,548 / 1,073
Market Cap (GBPm)	22,683
Avg. 6m daily volume (000)	3 606

ANALYSIS

- **Consolidated revenue** reached £19,605m up 11.5% on reported with lfl growth of 5% compared with 5.2% anticipated, after continue slowdown in Q4 (Q3 was up 5.2% with 9m up 5.6%). By geography, NA continues to drive revenue lfl growth up 8.1% (8% estimated after +8.3% after 9m) while Continental Europe was up 2.8% after challenging Q4 (Q3 was up 3.7% as 9m) and RoW was down 1.2% still impacted by offshore and remote business (9m was slightly positive of 0.2%).
- **Operating profit** was also a bit disappointed at £1,409m up 11.7% on reported with flat margin vs. 15bps anticipated.
- **2017 outlook:** Management expectations remain positive with nevertheless growth weighted to the second part of the year.

VALUATION

- At the current share price, the stock is trading at 14.7x EV/EBIT 2016-17e and 13.6x 2017-18e vs. median historical of 12.4x and CAGR EBIT 2015-2018e of 12x.

NEXT CATALYSTS

- Conference call at 9:30am (UK time)
- AGM + IMS on 2nd February 2017

[Click here to download](#)

Bruno de La Rochebrochard, bdelarochebrochard@bryangarnier.com

Luxury & Consumer Goods

Essilor

Price EUR101.80

FY 2016 outlook revised down again due to the US market

Fair Value Under Review

BUY

Bloomberg	EF FP
Reuters	ESSI.PA
12-month High / Low (EUR)	123.6 / 100.3
Market Cap (EURm)	22,202
Avg. 6m daily volume (000)	471.2

ANALYSIS

This morning, Essilor has again revised down its FY LFL growth guidance, **which is now expected to be "around 3.5%" vs. our estimate for 3.8%**, and we assume that the CS expectations were also close to our forecast.

According to the group, this third downward revision is again **due to lingering weakness in the US optical market (~44% of Lenses & Optical Instrument sales)** that has been negatively affecting Essilor since Q2 and irrespective of some one-off headwinds (Transitions, loss of two specific contracts). We understand that poor trends continued in October.

As a reminder, during the Q3 sales conference call, Essilor's management struggled to explain this unexpected slowdown in the prescription lens market ("wait-and-see" attitudes by consumers before the US elections?), on top of rather favourable macro indicators. Like other players in this industry, Essilor was caught by surprise as historically, there is a close correlation between macro and optical market trends.

In a backdrop of weaker-than-expected LFL growth and the dilutive impact from M&A, **the contribution margin target was also adjusted to "around 18.5%" vs. "around 18.8%"**, implying a 30bp decline vs. 2018.

VALUATION

Although Essilor continues to gain market share (even in the US: +1.3% LFL in Q3, +3% adjusted for Transitions and the loss of two very specific contracts vs. market slightly negative), its growth is mainly affected by an unexpected deceleration in the US market which should be flat this year after +3.5-4% last year.

Pending our new forecasts to reflect this new FY outlook, we have put our FV "under review".

NEXT CATALYSTS

Essilor will report its FY 2016 results on 17th February 2017.

[Click here to download](#)

	1 M	3 M	6 M	31/12/15
Absolute perf.	-3.0%	-9.2%	-11.1%	-11.5%
Consumer Gds	-4.3%	-6.0%	-2.5%	-7.0%
DJ Stoxx 600	-1.2%	0.0%	0.7%	-7.0%

	2015	2016e	2017e	2018e
P/E	28.5x	25.9x	23.7x	21.5x
Div yield (%)	1.1%	1.3%	3.1%	4.1%

Cédric Rossi, crossi@bryangarnier.com

Healthcare

Novo Nordisk

Price DKK227.30

Xultophy approved in the US

Fair Value DKK270 (+19%)

NEUTRAL

Bloomberg	NOVOB DC
Reuters	NOVOB.CO
12-month High / Low (DKK)	404.2 / 225.3
Market Cap (DKKm)	457,456
Avg. 6m daily volume (000)	3 611

	1 M	3 M	6 M	31/12/15
Absolute perf.	-19.9%	-26.4%	-36.7%	-43.2%
Healthcare	-3.5%	-6.8%	-4.7%	-13.9%
DJ Stoxx 600	-1.2%	0.0%	0.7%	-7.0%
	2015	2016e	2017e	2018e
P/E	16.8x	15.0x	14.7x	14.1x
Div yield (%)	2.8%	3.0%	3.1%	3.2%

ANALYSIS

- Together with Sanofi's Soliqua, Novo's Xultophy was approved yesterday by the US FDA as a treatment for type II diabetics whose disease remains uncontrolled despite use of either basal insulin or GL1 analogue. The label is very much as expected. It is good surprise for Novo to be approved one month ahead of schedule and simultaneously to Sanofi's Soliqua. However, it will not change much in terms of commercial capabilities and it looks like Sanofi will be first to launch, mentioning January 2017 when Novo-Nordisk talks about H1 2017.
- It's good to see that the agency did not require any further work before approving the two products but now another tough part of the job is starting with the discussions with payers to have Soliqua and Xultophy on the lists. Of course, an estimated 2 million of basal insulin takers are uncontrolled in the US and probably half of them are candidates to take a fixed-dose combination. But payers are in a good shape to ask for deep discounts and from that perspective, although Xultophy might be seen as a superior product to Soliqua, Sanofi has a significantly greater latitude to offer attractive pricing than Novo-Nordisk which has to protect the profitability of its GLP1 franchise. It will be interesting to see how Sanofi prices Soliqua in January compared to Victoza alone.

VALUATION

- Because Xultophy had already been approved in the EU, we had a 100% PoS for the drug and our PS is USD2.5bn in 2022. There is no reason at this stage to make any change to the numbers.

NEXT CATALYSTS

- January 2017: US launch of Soliqua (including pricing elements)

[Click here to download](#)Eric Le Berrigaud, eleberrigaud@bryangarnier.com

Healthcare

Sanofi

Price EUR75.70

Sanofi can try to defend its Diabetes franchise with Soliqua

Fair Value EUR84 (+11%)

NEUTRAL

Bloomberg	SAN FP
Reuters	SASY.PA
12-month High / Low (EUR)	84.4 / 67.3
Market Cap (EURm)	97,610
Avg. 6m daily volume (000)	2 589

ANALYSIS

Yesterday Soliqua obtained approval from the FDA for marketing in the US under an unexpected strength and a unique pen device containing 100 units/mL of glargine and 33 mcg/mL of lixisenatide, which is very likely the answer provided by Sanofi to the questions raised by the AdCom panel and probably by the FDA too about the risk of misuse with the initial two pens. The new offer is no longer differentiated from Novo's but is much easier for the patient. The range of daily units that can be delivered by the pen is unchanged.

As far as we can see, the label is not surprising and makes Soliqua (as well as Xultophy) the treatment of choice for people with type II diabetes that are not controlled with either a basal insulin like Lantus or a GLP1 analogue. For Sanofi clearly, the target population is Lantus users not at goal (i.e. with A1c>7%). This represents a population of about 2m people and our estimate is that half of them might migrate to a fixed-dose combination. As a consequence, this market could reach USD4-5bn in value.

Price negotiations will start shortly with payers. We have assumed that Lyxumia would be priced at a 40% discount to Victoza and would carry a mandatory rebate of 20% on average whereas Soliqua would be priced at a 40% premium to Lyxumia i.e. around or slightly below Victoza alone.

VALUATION

We are making no change to our estimates so far and will wait until January and the first indicators on pricing to fine-tune our numbers. This is good news for Sanofi's Diabetes franchise because Soliqua should help mitigate the decline in the glargine product line.

NEXT CATALYSTS

January 2017: EU decision on Soliqua and US launch of Soliqua

[Click here to download](#)

Eric Le Berrigaud, eleberrigaud@bryangarnier.com

	1 M	3 M	6 M	31/12/15
Absolute perf.	9.4%	8.6%	6.4%	-3.7%
Healthcare	-3.5%	-6.8%	-4.7%	-13.9%
DJ Stoxx 600	-1.2%	0.0%	0.7%	-7.0%

	2015	2016e	2017e	2018e
P/E	13.5x	13.5x	13.8x	12.5x
Div yield (%)	3.9%	4.0%	4.2%	4.6%

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 56.1%

NEUTRAL ratings 32.5%

SELL ratings 11.5%

Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/Infrastructures/Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Automotive & Parts		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle Prudential et de Résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11



BRYAN, GARNIER & Co

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....